ArticleCureus2026
Prognostic Nutritional Index as a Predictor of Treatment-Related Toxicity in Head and Neck Cancer Patients Undergoing Chemoradiotherapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The Prognostic Nutritional Index (PNI) is a straightforward marker that reflects nutritional and inflammatory status, derived from serum albumin and lymphocyte count. The significance of predicting treatment-related toxicity in patients with head and neck cancer (HNC) receiving radiotherapy in conjunction with chemotherapy continues to hold clinical importance. This study aimed to assess the predictive capability of baseline PNI regarding severe acute and late radiation-induced toxicities (mucositis, dysphagia, xerostomia, weight loss)in HNC patients undergoing radiotherapy with either induction or concurrent chemotherapy. Methodology This retrospective cohort study comprised 150 patients with HNC who received treatment at a tertiary center from January 2021 to December 2025. The PNI was determined utilizing Onodera's formula, and patients were classified into low (<49.0) and high (≥49.0) PNI categories. The outcomes evaluated comprised severe acute toxicity (Common Terminology Criteria for Adverse Events, version 4.0 grade ≥3), weight loss exceeding 10% during treatment, and late toxicities (grade ≥2). Analyses using multivariable logistic and Cox regression were conducted. Results The median PNI was recorded at 49.0, with 50% of participants classified as having low PNI. Severe acute toxicity was observed in 64% of patients, whereas 20% experienced notable weight loss. Patients with low PNI experienced greater weight loss (32% compared to 8%) and a heightened risk after adjustment (odds ratio = 4.12). A low PNI was similarly linked to the occurrence of late mucositis (hazard ratio = 1.82). Conclusions A low baseline PNI serves as a predictor for treatment-related toxicity and may assist in identifying high-risk HNC patients who would benefit from early nutritional intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.